We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms and Conditions of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Glaxo's (GSK) Pharmaceutical and Consumer Healthcare segments are likely to have driven third-quarter sales. Results will provide clarity on the impact of coronavirus on the company's vaccine business.
The biotech sector was in focus as Biogen's (BIIB) Q3 results disappoint, Vertex (VRTX) stops study and Regeneron's (REGN) Ebola drug gets FDA approval.
Clinical studies on coronavirus vaccine candidates of AstraZeneca (AZN) and J&J (JNJ) which were paused for reviewing adverse events are anticipated to resume as early as this week.
When it comes to valuation metrics, though P/E and P/S are the first choices, the P/B ratio is also emerging as a convenient tool to identify low-priced stocks that have high-growth prospects.
AstraZeneca's (AZN) regulatory application for label expansion of Tagrisso to include adjuvant treatment of patients with early-stage EGFR-mutated lung cancer gets FDA's apriority review.
The CHMP passes a favorable opinion for the approval of AstraZeneca's (AZN) Forxiga for the treatment of symptomatic chronic HFrEF in adults with and without type-II diabetes.
AbbVie (ABBV) files regulatory applications with the FDA and the EMA, seeking approval for a new indication of Rinvoq ??? atopic dermatitis. The drug is already marketed to treat rheumatoid arthritis.
Robust sales growth is an important characteristic of potential stock market winners. Let's check out - Vertex Pharmaceuticals (VRTX), PerkinElmer (PKI), Stanley Black & Decker (SWK), 3M Company (MMM) and Arthur J. Gallagher (AJG) - as these are likely to see solid sales growth.
Higher sales of Pfizer's (PFE) key brands, Eliquis, Ibrance and Inlyta, in the Biopharma segment are likely to have made up for lower sales in the Upjohn group in the third quarter.
Roche (RHHBY) and partner AbbVie obtain full FDA approval for leukemia drug, Venclexta, in combination with Vidaza or Dacogen or low-dose cytarabine (LDAC).
Lilly (LLY) inks a deal to acquire Disarm Therapeutics for an upfront payment of $135 million to strengthen its pain and neurological diseases portfolio.
pharmaceuticals: Archive
Roche (RHHBY) Inks Deal to Develop Oral Coronavirus Treatment
by Zacks Equity Research
Roche (RHHBY) signs a contract with privately-held Atea Pharmaceuticals for jointly developing AT-527, an oral treatment for COVID-19 patients.
RHHBY LLY GSK VIR
pharmaceuticals
Novartis (NVS) Gets Orphan Drug Tag for Huntington's Disease Drug
by Zacks Equity Research
Novartis (NVS) gets orphan drug designation for branaplam (LMI070) in Huntington's disease.
PFE MRK NVS BMY
pharmaceuticals
Is a Beat in Store for Glaxo (GSK) This Earnings Season?
by Zacks Equity Research
Glaxo's (GSK) Pharmaceutical and Consumer Healthcare segments are likely to have driven third-quarter sales. Results will provide clarity on the impact of coronavirus on the company's vaccine business.
PFE MRK GSK NVS
pharmaceuticals
Stimulus or No? Plus News from GILD, Earnings from INTC & MAT
by Mark Vickery
Gilead (GILD) shares are up 4% in late trading on an announcement that the FDA has granted full approval to its remdesivir treatment.
MAT INTC GILD
earnings pharmaceuticals tech-stocks
Biotech Stock Roundup: BIIB Posts Q3 Results, VRTX Stops Study & Other Updates
by Zacks Equity Research
The biotech sector was in focus as Biogen's (BIIB) Q3 results disappoint, Vertex (VRTX) stops study and Regeneron's (REGN) Ebola drug gets FDA approval.
BIIB REGN GILD VRTX BSTC CRSP
biotechs pharmaceuticals
AstraZeneca (AZN), J&J (JNJ) Coronavirus Trials May Resume Soon
by Zacks Equity Research
Clinical studies on coronavirus vaccine candidates of AstraZeneca (AZN) and J&J (JNJ) which were paused for reviewing adverse events are anticipated to resume as early as this week.
JNJ AZN PFE MRNA
pharmaceuticals
6 Low Price-to-Book Stocks That May Prove to be Solid Bets
by Kinjel Shah
When it comes to valuation metrics, though P/E and P/S are the first choices, the P/B ratio is also emerging as a convenient tool to identify low-priced stocks that have high-growth prospects.
BEN TEVA SPB CNC VIAC ATCO
consumer-staples finance pharmaceuticals retail
Prothena (PRTA) to Advance Parkinson's Disease Drug to Phase II
by Zacks Equity Research
Prothena (PRTA) and partner Roche (RHHBY) plan to advance prasinezumab into a phase IIb study in patients with early Parkinson's disease.
RHHBY BMY EBS PRTA
pharmaceuticals
Aclaris (ACRS) Begins Phase II Study on Eczema Candidate
by Zacks Equity Research
Aclaris (ACRS) initiates a phase IIa study on ATI-1777, for the treatment of moderate-to-severe atopic dermatitis.
ACRX ABBV ACRS AMRX
pharmaceuticals
AstraZeneca's (AZN) Tagrisso sNDA Receives Priority Review
by Zacks Equity Research
AstraZeneca's (AZN) regulatory application for label expansion of Tagrisso to include adjuvant treatment of patients with early-stage EGFR-mutated lung cancer gets FDA's apriority review.
AZN RHHBY MRK VRTX
pharmaceuticals
Merck (MRK) to Report Q3 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
Investor focus is likely to be on the sales numbers of Merck's (MRK) blockbuster oncology medicine, Keytruda.
AZN MRK GSK SGEN
pharmaceuticals
Merck (MRK) Pneumococcal Vaccine Meets Late-Stage Study Goals
by Zacks Equity Research
Merck's (MRK) investigational 15-valent pneumococcal conjugate vaccine meets primary immunogenicity objectives in two late-stage studies in adults.
PFE MRK MRNA GSK
pharmaceuticals
Verizon (VZ), Abbott (ABT), Thermo Fisher (TMO) Report Q3; Tesla (TSLA) After the Bell
by Mark Vickery
Thermo Fisher (TMO) posted a big beat this morning, while Verizon (VZ) and Abbott (ABT) topped expectations more mildly.
VZ CSX ABT CMG TMO TSLA
communications earnings medical pharmaceuticals
Will Lilly (LLY) Witness Recovery in Sales in Q3 Earnings?
by Zacks Equity Research
Higher demand for its growth drugs is likely to have offset generic competition for several other drugs to boost Lilly's (LLY) third-quarter sales.
GILD MRK LLY GSK
pharmaceuticals
The Zacks Analyst Blog Highlights: Amazon, Home Depot, Sanofi, Intel and AMT
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amazon, Home Depot, Sanofi, Intel and AMT
AMT HD AMZN INTC SNY
internet pharmaceuticals retail
AstraZeneca (AZN) Gets CHMP Nod for Forxiga in Heart Failure
by Zacks Equity Research
The CHMP passes a favorable opinion for the approval of AstraZeneca's (AZN) Forxiga for the treatment of symptomatic chronic HFrEF in adults with and without type-II diabetes.
JNJ AZN LLY VRTX
pharmaceuticals
AbbVie (ABBV) Files for Rinvoq in Atopic Dermatitis in US & EU
by Zacks Equity Research
AbbVie (ABBV) files regulatory applications with the FDA and the EMA, seeking approval for a new indication of Rinvoq ??? atopic dermatitis. The drug is already marketed to treat rheumatoid arthritis.
BIIB NVS AMGN ABBV
pharmaceuticals
Bet on These 5 Top-Ranked Stocks With Strong Sales Growth
by Swayta Shah
Robust sales growth is an important characteristic of potential stock market winners. Let's check out - Vertex Pharmaceuticals (VRTX), PerkinElmer (PKI), Stanley Black & Decker (SWK), 3M Company (MMM) and Arthur J. Gallagher (AJG) - as these are likely to see solid sales growth.
MMM PKI SWK VRTX AJG
biotechs computers finance industrial-products insurance multi-sector-conglomerates pharmaceuticals
Pfizer (PFE) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Higher sales of Pfizer's (PFE) key brands, Eliquis, Ibrance and Inlyta, in the Biopharma segment are likely to have made up for lower sales in the Upjohn group in the third quarter.
PFE MRK GSK BNTX
pharmaceuticals
Vertex Pharmaceuticals (VRTX) Enters Oversold Territory
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
VRTX
pharmaceuticals
Top Analyst Reports for NVIDIA, salesforce & AstraZeneca
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including NVIDIA (NVDA), salesforce.com (CRM) and AstraZeneca (AZN).
NVDA JPM CVX CRM CHTR AZN
computers consumer-discretionary finance oil-energy pharmaceuticals semiconductor tech-stocks
5 Big Pharma/Biotech Stocks Set to Trump Q3 Earnings Estimates
by Zacks Equity Research
Let us take a look at some drug/biotech stocks including Glaxo (GSK) and Merck (MRK) that are poised to beat on earnings for the third quarter.
MRK GSK BMY VRTX SGEN
biotechs pharmaceuticals
Roche (RHHBY), AbbVie's Leukemia Drug Venclexta Get Full FDA Nod
by Zacks Equity Research
Roche (RHHBY) and partner AbbVie obtain full FDA approval for leukemia drug, Venclexta, in combination with Vidaza or Dacogen or low-dose cytarabine (LDAC).
REGN SNY RHHBY ABBV
pharmaceuticals
Top Stock Reports for Amazon, Home Depot & Sanofi
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Amazon.com (AMZN), The Home Depot (HD) and Sanofi (SNY).
SNY SAP INTC HD AMZN AMT
computers construction internet pharmaceuticals reit retail semiconductor
Lilly to Acquire Private Biotech for Boosting Pain Portfolio
by Zacks Equity Research
Lilly (LLY) inks a deal to acquire Disarm Therapeutics for an upfront payment of $135 million to strengthen its pain and neurological diseases portfolio.
PFE LLY VRTX ITCI
pharmaceuticals